Weiss J N, Badlani G H, Ravalli R, Brettschneider N
Long Island Jewish Medical Center, Department of Urology, New Hyde Park, New York 10040, USA.
Int J Impot Res. 1994 Sep;6(3):171-4.
One hundred and eighty patients, average age of 58 years (range 24-75) were evaluated for impotence and were advised to undergo pharmacologic self-injection therapy with either papaverine/Regitine (90%) or prostaglandin E1 (10%). Follow-up was available from 2 months to 3 years (average 11 months). The cause of impotence was determined by hormonal testing, Rigiscan and psychological testing. The etiology of impotence was organic (70%), psychogenic (20%), and mixed (10%). After the initial test injection 22% of patients did not enroll in the self-injection program or were lost to follow-up. The group with psychogenic impotence had the highest satisfaction/usage rate at 42%. Overall only 20% of patients were satisfied long-term and were actively using self-injection therapy. Of the 140 patients available for follow-up, 112 patients (80%) discontinued self-injection therapy. The reasons for discontinued usage were alternate treatment (prosthesis or vacuum device) 15%, return or improvement of erections 8%, partner dissatisfaction or loss of partner 10%, or complications of injection therapy 10%. Cost was not a factor for discontinued use. Loss of interest caused 57% of patients to stop using self-injection therapy. Although pharmacologic self-injection therapy is initially promising there is a high drop-out rate at long-term follow-up.
180名平均年龄58岁（范围24 - 75岁）的患者因阳痿接受评估，并被建议采用罂粟碱/酚妥拉明（90%）或前列腺素E1（10%）进行药物自我注射治疗。随访时间为2个月至3年（平均11个月）。通过激素检测、阴茎硬度测试仪和心理测试确定阳痿的病因。阳痿的病因是器质性的（70%）、心因性的（20%）和混合性的（10%）。在首次试验注射后，22%的患者未参加自我注射计划或失访。心因性阳痿组的满意度/使用率最高，为42%。总体而言，只有20%的患者长期满意并积极使用自我注射治疗。在可供随访的140名患者中，112名患者（80%）停止了自我注射治疗。停止使用的原因包括替代治疗（假体或真空装置）15%、勃起恢复或改善8%、伴侣不满意或失去伴侣10%或注射治疗并发症10%。费用不是停止使用的因素。兴趣丧失导致57%的患者停止使用自我注射治疗。虽然药物自我注射治疗最初很有前景，但长期随访的退出率很高。
